Skip to main content

Tenolam-D

A Tenofovir/Lamivudine/Dolutegravir brand by Mylan/Viatris — tablet, made in India.

NAFDAC registration

We don't have a NAFDAC registration number on record for this brand. Every registered medicine sold in Nigeria carries one on its pack — check the pack and verify the number before buying.

Tenolam-D at a glance

Manufacturer
Mylan/Viatris
Form
Tablet
Strength
Tenofovir 300mg/Lamivudine 300mg/Dolutegravir 50mg
Made in
India
NAFDAC reg. no.
not on our records

Tenolam-D price in Nigeria

Prices for Tenofovir/Lamivudine/Dolutegravir products vary by brand, strength, and pack size — check current prices at a licensed pharmacy, or tell us what you need and we'll connect you with a verified source.

About Tenofovir/Lamivudine/Dolutegravir

Tenofovir/Lamivudine/Dolutegravir, commonly known as TLD, is a fixed-dose combination antiretroviral tablet used for the treatment of HIV-1 infection. It combines three powerful antiretroviral medicines into a single pill: Tenofovir disoproxil fumarate (300mg), an NRTI that blocks the HIV reverse transcriptase enzyme; Lamivudine (300mg), another NRTI that works similarly to tenofovir but targets a different step in viral replication; and Dolutegravir (50mg), an integrase strand transfer inhibitor (INSTI) that prevents HIV from inserting its genetic material into human cells. Nigeria has the second largest HIV burden in the world, with approximately 1.9 million people living with HIV, and TLD has become the cornerstone of the national antiretroviral therapy programme. The shift to TLD represents a major advance in HIV treatment in Nigeria, offering superior viral suppression with fewer side effects compared to older regimens.

Read the full Tenofovir/Lamivudine/Dolutegravir guide — dosage, side effects, warnings, and all registered brands.

Frequently asked questions

Registration details are shown exactly as recorded in the NAFDAC Greenbook (our copy: August 2026). Listings can lag renewals — always confirm current status on the official Greenbook before acting on it. Content updated August 2026.